U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H12NO2P
Molecular Weight 161.1387
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TPMPA

SMILES

CP(O)(=O)C1=CCNCC1

InChI

InChIKey=MFUKVPOVVKKLRQ-UHFFFAOYSA-N
InChI=1S/C6H12NO2P/c1-10(8,9)6-2-4-7-5-3-6/h2,7H,3-5H2,1H3,(H,8,9)

HIDE SMILES / InChI
Molecular Formula C6H12NO2P
Molecular Weight 161.1387
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

(1,2,5,6-tetrahydropyridine-4-yl)methylphosphinic acid (TPMPA) is a competitive antagonist of gamma-aminobutyric acid (GABA)C receptors.

CNS Activity

CNS Active

Originator

Ragozzino, D. et al.

Approval Year

Unknown

Targets

Primary TargetPharmacologyConditionPotency
GABA-C receptor
Antagonist

Conditions

ConditionModalityTargetsHighest PhaseProduct
Retinitis pigmentosa
 Primary
Preclinical
Unknown

PubMed

Patents

US5627169A

Sample Use Guides

In Vivo Use Guide
TPMPA (100 μmol/rat) was administered intracerebroventricularly (ICV)
Route of Administration: Other
In Vitro Use Guide
Muscimol (100 μM) caused a transient increase of the [Ca(2+)]i in RPE cells regardless of whether Ca(2+) was added to the buffer. Muscimol-induced increases in the [Ca(2+)]i were inhibited by pretreatment with picrotoxin (300 μM) or TPMPA (500 μM).
Substance Class Chemical
Record UNII
TR7I0800L2
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966